Crystalline forms of a pharmaceutical compound

Details Crystalline forms of a pharmaceutical compound Crystalline forms of a pharmaceutical compound

2005-02-24

2011-12-13

Coleman, Brenda (Department: 1624)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Heterocyclic carbon compounds containing a hetero ring...

C540S545000

Reexamination Certificate

active

08076320

ABSTRACT:
Described are crystalline forms of the pharmaceutical compound “[9S-(9α,10β,12α)]-5,16-Bis[(ethylthio)methyl]-2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-9, 12-epoxy-1H-diindolo[1,2,3-fg:3′,2′,1′-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid methyl ester”, as well as methods for their use and preparation.

REFERENCES:
patent: 5621100 (1997-04-01), Lewis et al.
patent: 0 651 754 (1997-04-01), None
patent: 1 121 932 (2001-08-01), None
patent: WO-94/02488 (1994-02-01), None
patent: WO97/49406 (1997-12-01), None
Kaneko M. et al: “Neurotrophic 3, 9-Bis '(alkylthio)methyll—and—Bis(alkoxymethyl)-K-252a Derivatives” Journal of Medicine Chemistry, American Chemical Society. Washington, US, vol. 40, No. 12, 1997, pp. 1863-1869, XP002128804 ISSN: 0022-2623.
Saporito et al., “Preservation of Cholinergic Activity and Prevention of Neuron Death by CEP-1347/KT-7515 Following Excitotoxic Injury of the Nucleus Basalis Magnocellularis”, Neuroscience (1998), vol. 86(2), pp. 461-472.
Ylikoski et al., “Blockade of c-Jun N-terminal kinase pathway attenuates gentamicin-induced cochlear and vestibular hair cell death”, Hearing Res. (2002), vol. 166, pp. 33-43.
Murakata et al., “Mixed Lineage Kinase Activity of Indolocarbazole Analogues”, Bioorg. Med. Chem. Lett. (2002), vol. 12, pp. 147-150.
Maroney et al., “Mixed Lineage Kinase Family, Potential Targets for Preventing Neurodegeneration”, Curr. Med. Chem.—Central Nervous System Agents (2002), vol. 2, pp. 143-155.
Bozyczko-Coyne et al., “CEP-1347/KT-7515, an inhibitor of SAPK/JNK pathway activation, promotes survival and blocks multiple events associated with AB-induced cortical neuron apoptosis”, J. Neurochemistry (2001), vol. 77, pp. 849-863.
Bodner et al., “Mixed lineage kinase 3 mediates gp120IIIB-induced neurotoxicity”, J. Neurochemistry (2002), vol. 82, pp. 1424-1434.
Pirvola et al., “Rescue of Hearing, Auditory Hair Cells, and Neurons by CEP-1347/KT7515, an Inhibitor of c-Jun N-Terminal Kinase Activation”, J. Neuroscience (2000), vol. 20(1), pp. 43-50.
Saporito et al., “Discovery of CEP-1347/KT-7515, an Inhibitor of the JNK/SAPK Pathway for the Treatment of Neurodegenerative Diseases”, Progress in Medicinal Chemistry (2002), vol. 40, pp. 23-62.
Mucke, “CEP-1347 Cephalon”, IDRUGS (2003), vol. 6(4), pp. 377-383.

Affiliated with

Also associated with

Rating

Crystalline forms of a pharmaceutical compound does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Crystalline forms of a pharmaceutical compound, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Crystalline forms of a pharmaceutical compound will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4315358